Tag Archives: I/O

Immuno-Oncology: The Comeback Kid
July 13, 2021

By Tim Reilly & Jonathan Montagu, CDO and CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4)

Leave a comment

I/O: The Strategic Supernova In Cancer Today
June 22, 2016

With the big cancer confab ASCO 2016 fading into memory, R&D teams everywhere are getting back to work on their cancer programs – and across the industry many of them will be doing the same work, on the same targets,